Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. Show more
Location: 3 World Trade Center, New York, NY, 10007, United States | Website: https://metsera.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
3.747B
52 Wk Range
$12.30 - $47.40
Previous Close
$37.25
Open
$37.44
Volume
1,612,378
Day Range
$35.41 - $37.55
Enterprise Value
3.217B
Cash
530.9M
Avg Qtr Burn
-44.49M
Insider Ownership
17.71%
Institutional Own.
84.26%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2b Data readout | ||
Phase 1 Data readout | ||
Phase 1 Data readout | ||
Phase 1 Data readout |